Élodie Vauléon

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial

Antonio Omuro, Alba A. Brandes, Ahmed Idbaïh et al. · Neuro-Oncology · 2022 · 435 citations · Full text

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

Julien Edeline, Éveline Boucher, Yan Rolland et al. · Cancer · 2011 · 271 citations · Full text

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Karim Fizazi, Aline Maillard, Nicolas Penel et al. · Annals of Oncology · 2019 · 240 citations · Full text

Malignant Disease, Medicine, Phase Iii Trial +8

DNA methylation in glioblastoma: impact on gene expression and clinical outcome

Amandine Etcheverry, Marc Aubry, Marie de Tayrac et al. · BMC Genomics · 2010 · 218 citations · Full text

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11